Guide on Access to the Yellow Fever ICG Stockpile. Emergency Campaigns. International Coordinating Group on Vaccine. Geneva, Switzerland 2012

Similar documents
Measles and Rubella Initiative Outbreak Response Fund Standard Operating Procedures, effective 01 April 2017

World Health Organization Emerging and other Communicable Diseases, Surveillance and Control

World Health Organization Emerging and other Communicable Diseases, Surveillance and Control

International Coordinating Group for vaccine provision. Emergency Vaccine Stockpiles

Establishing a cholera stockpile: What do we need? Alejandro Costa Epidemic Readiness and Intervention

RESIDENT / HUMANITARIAN COORDINATOR REPORT ON THE USE OF CERF FUNDS ANGOLA RAPID RESPONSE YELLOW FEVER 2016

Meningitis Vaccine Procurement

THE SITUATION OF YELLOW FEVER IN THE AFRICAN REGION: THE PLAN TO END YF EPIDEMICS IN 2026

Overview of Measlescontaining. through UNICEF. Overview of [VACCINE] through UNICEF

Safe Injection Equipment

Yellow fever. Key facts

Navigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 5. Can my country afford a JE vaccination program?

CÔTE D IVOIRE: YELLOW FEVER IN ABIDJAN

SITUATION REPORT YELLOW FEVER 20 MAY 2016 SUMMARY

What is this document and who is it for?

EBOLA VIRUS DISEASE. Democratic Republic of Congo. External Situation Report 1. Credit : B.Sensasi / WHO Uganda-2007

Navigating vaccine introduction: a guide for decision-makers JAPANESE ENCEPHALITIS (JE) Module 4. How should my country introduce JE vaccines?

Managing constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October Bangkok,

Report to the Board 7-8 December 2016

INTERVIEW GUIDE FOR THE EPI MANAGEMENT LEVEL GENERAL INFORMATION

EBOLA VIRUS DISEASE. Democratic Republic of Congo. External Situation Report 2. Credit : B.Sensasi / WHO Uganda-2007

Government of Bangladesh

The power of partnership: the GAVI Alliance Board

Meningococcal Vaccine ICG stockpile 2016

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

SITUATION REPORT YELLOW FEVER 28 JULY 2016 SUMMARY

Report to the Board 6-7 June 2018

EBOLA VIRUS DISEASE. Page 1

YELLOW FEVER UPDATE. DPGH Meeting Dr. Grace Saguti NPO/DPC 13 July 2016

FRAMEWORK FOR IMPLEMENTING THE GLOBAL STRATEGY TO ELIMINATE YELLOW FEVER EPIDEMICS (EYE), IN THE AFRICAN REGION. Report of the Secretariat

PLAGUE OUTBREAK. Madagascar. External Situation Report 02. Grade

SITUATION REPORT YELLOW FEVER 26 MAY 2016 SUMMARY

SITUATION REPORT YELLOW FEVER 15 JULY 2016 SUMMARY

Ensuring the quality of polio outbreak response activities: A rationale and guide for 3 month, quarterly and 6 month independent assessments

2016 Grant Application Form

Vaccines Supply Shortages Challenges & Opportunities

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance

Polio and routine immunisation Alan Brooks

SITUATION REPORT YELLOW FEVER 16 JUNE 2016 SUMMARY

EBOLA VIRUS DISEASE. On 26 May 2017, no new confirmed or probable EVD cases were reported. The last confirmed case was reported on 11 May 2017.

EBOLA VIRUS DISEASE. Democratic Republic of the Congo. External Situation Report 21. Date of information: 05 June

SITUATION REPORT YELLOW FEVER 8 JULY 2016 SUMMARY

IMMUNIZATION IN HUMANITARIAN RESPONSE and PARTNER COORDINATION. GAVI Board - 13 June 2017, Geneva

Gavi, the Vaccine Alliance Co-financing Policy Version 2.0

Diabetes Action Now. Consultation on a new WHO-IDF programme

SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT

Yellow Fever Vaccine: Current Outlook. UNICEF Supply Division

Report to the. GAVI Alliance Board November 2013

PLAGUE OUTBREAK. Madagascar. External Situation Report 01. Grade

EBOLA VIRUS DISEASE. Page 1

EXTERNAL EVALUATION OF THE INTERNATIONAL COORDINATING GROUP ON VACCINE PROVISION (ICG) MECHANISM

Global deployment of Oral Cholera Vaccine (OCV) Dipika Sur MD Consultant THSTI, India

YELLOW FEVER OUTBREAK IN ANGOLA INCIDENT MANAGEMENT

Q&A on trial of Ebola Virus Disease vaccine in Guinea

GAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE

Zika Virus Update for Emergency Care Providers

How to Detect and Confirm Epidemic Yellow Fever

Situation Manual. 170 Minutes. Time Allotted. Situation Manual Tabletop Exercise 1 Disaster Resistant Communities Group

EBOLA VIRUS DISEASE. Democratic Republic of the Congo. External Situation Report 22. Date of information: 08 June

Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning

Sudan EPI Benefits From Polio Eradication Program

Fact sheet. Yellow fever

WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES

Vaccine Decision-Making

MICHIGAN OFFICE OF SERVICES TO THE AGING. Operating Standards For Service Programs

Ex Post-Evaluation Brief India: Polio Immunisation Programme, Phases I to VII

Measles Containing Vaccines. UNICEF Supply Division Industry Consultation Meeting January 2012

Summary of Definitions of Mission and Strategic Goal Level Indicators. in GAVI Alliance Strategy Updated October 2013

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

Fifth report of Committee A

Access to affordable vaccines in Emergency and Humanitarian Response June 20, 2016

Determining the Feasibility of an Oral Cholera Vaccination (OCV) Campaign

VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...

PROJECT INFORMATION DOCUMENT (PID) CONCEPT STAGE Report No.: AB2282 Project Name

YELLOW FEVER OUTBREAK IN ANGOLA INCIDENT MANAGEMENT

THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability

Guideline for Antiviral Drugs

SITUATION REPORT YELLOW FEVER 5 AUGUST 2016 SUMMARY

YELLOW FEVER OUTBREAK IN ANGOLA INCIDENT MANAGEMENT

6. SURVEILLANCE AND OUTRBREAK RESPONSE

INDIVIDUAL CONSULTANT PROCUREMENT NOTICE

Yellow fever Vaccine investment strategy

Gavi Secretariat Update: Progress, priorities and strategies

EBOLA VIRUS DISEASE. Democratic Republic of Congo. External Situation Report 2 Date of issue: 16 May Situation update

Report to the. GAVI Alliance Board June 2013

Preparedness plan against Chikungunya and dengue dissemination in mainland France Public Health perspective

EBOLA VIRUS DISEASE. Democratic Republic of the Congo. External Situation Report 16. Date of information: 29 May

Sudan Measles Situation Report

EBOLA VIRUS DISEASE. Democratic Republic of the Congo. External Situation Report 25. Date of information: 19 June

Access to vaccination in GAVI countries and at global level

EBOLA SITUATION REPORT

Implementation of the International Health Regulations (2005)

Weekly Report on Activities (EHA/HAC)

Gavi initiatives for improving vaccine supply

Diphtheria Outbreak Response Cox s Bazar Bangladesh

Pandemic Influenza Preparedness and Response

Vaccine introduction guidelines

ANGOLA Humanitarian Situation Report

Transcription:

Guide on Access to the Yellow Fever ICG Stockpile Emergency Campaigns Geneva, Switzerland 2012 International Coordinating Group on Vaccine Provision for Yellow Fever Control

TABLE OF CONTENTS 1. Description of the Global Yellow Fever Vaccine Stockpile 1 2. Conditions to access the Yellow Fever Vaccine Stockpile 2 3. How to apply for vaccine in the ICG Stockpile? 3 4. What are the criteria for the release of the vaccine? 5 5. How much does it cost? 5 6. How to get vaccine when the ICG Stockpile is depleted? 6 ANNEXES 1. Yellow Fever Vaccine Request for emergency campaigns. Essential application information 2. Yellow Fever Epidemiological Assessment Form (emergency campaigns) 3. Yellow Fever Vaccine Order Form (emergency campaigns)

1. Description of the Global Yellow Fever Vaccine Stockpile A mass vaccination campaign is the most effective public health strategy to control Yellow Fever (YF) outbreaks. It helps to limit the spread of the disease and so reduces mortality. In an emergency situation it is often difficult to get enough vaccine doses to protect the entire population at risk. In 2001, because there was a shortage of YF vaccine during the outbreak in Guinea, a global reserve of 2 million doses of vaccine was created to ensure a rapid response to outbreaks in the future. In 2003, this reserve was increased to 6 million doses with support from the Global Alliance for Vaccination and Immunization (GAVI). In December 2005, the GAVI board approved the "Yellow Fever vaccine stockpile investment case", increasing significantly its support to reduce the risk of Yellow Fever epidemics until 2013. The stockpile is managed by the International Coordinating Group on Vaccine Provision for Yellow Fever Control (YF-ICG) created in 2001. The YF-ICG consists of representatives from the World Health Organization (WHO), United Nations Children's Fund (UNICEF), Médecins sans Frontières (MSF) and the International Federation of Red Cross and Red Crescent Societies (IFRC). WHO/Headquarters in Geneva, Switzerland, serves as its Secretariat. The role of the YF-ICG is to verify that eligibility criteria are met by countries applying for outbreak support from the stockpile and to decide on the amount of vaccine to be shipped according to the needs expressed in the request. This guide explains how countries facing YF epidemics can apply for support from the Yellow Fever outbreak vaccine stockpile. Any country facing a YF epidemic is eligible to receive vaccines Version 2012 - May 1 Page 1 of 15

from the emergency vaccine stockpile. GAVI eligible countries may also apply for financial support to emergency vaccination campaign operational costs. In order to ensure the sustainability of the Yellow Fever Outbreak Stockpile, all countries that receive vaccine and materials from this stockpile should reimburse their cost, including shipping expenses. (See Section 5 - How much does it cost?). The added value of the global vaccine stockpile is the rapid availability of safe vaccine (from WHO pre-qualified manufacturers only) at affordable prices. 2. Conditions to access the Yellow Fever Vaccine Stockpile? The following conditions need to be fulfilled to apply for vaccine: at least one of the YF cases has been laboratory confirmed 1 ; careful assessment of the epidemic risk has been done in order to differentiate the start of an epidemic from sporadic cases due to sylvatic transmission; provide a "Vaccination Plan" for the immunization campaign together with the request; the request has been reviewed and approved by the national epidemic coordination body in order to ensure a well coordinated epidemic response in case many partners are involved; If implemented through an agency, it should show extensive experience in conducting a mass vaccination campaign. For further information/assistance regarding those conditions, please contact the Yellow Fever focal point at WHO, e-mail: ICGsecretariat@who.int or outbreak@who.int 1 The WHO case definition for Yellow Fever outbreak is to have at least one laboratory confirmed case. For reference, see Yellow fever surveillance and outbreak response: revision of case definitions, October 2010. Weekly Epidemiological Record, 2010, 85:465-472, http://www.who.int/wer/2010/wer8547/en/index.html Version 2012 - May 2 Page 2 of 15

3. How to apply for vaccine in the ICG Stockpile? To apply for vaccine in the stockpile, the country needs to send a written request to the ICG Secretariat. The request should be submitted through the Yellow Fever Request Document (see Annex 1). This document consists of two forms: 1) Yellow Fever Epidemiological Assessment Form to specify the magnitude and urgency of the epidemic (see Annex 2); 2) Yellow Fever Vaccine Order Form to request the vaccine (see Annex 3). The requesting country should be aware that the YF-ICG s decision regarding the release of vaccine from the ICG stockpile is based on the information provided. Therefore, it is important to complete the documents correctly and thoroughly. If the documents are not completed adequately, the YF- ICG Secretariat will ask for clarification, which may delay the whole process. In this regard, when a request will be submitted by a WHO country office, the support of the WHO regional office (i.e. AFRO Inter Country Support Team) can be very useful in ensuring an adapted vaccination strategy and properly filled ICG request. The documents should be sent to the YF-ICG Secretariat by email at: outbreak@who.int ICGsecretariat@who.int or outbreak@who.int (see figure 1-step 1). In case the internet connection is not working, contact the HSE/PED/Yellow Fever Focal Point in WHO Geneva - Switchboard telephone number : +41 22 791 2111 After the documents are received, the following process will be initiated (see figure 1): Version 2012 - May 3 Page 3 of 15

The YF-ICG Secretariat will summon the YF-ICG Committee (2). The documents will be reviewed and a decision will be taken, usually within two working days. When the YF-ICG Committee accepts the request (3), the YF-ICG Secretariat will authorize the UNICEF Supply Division (UNICEF SD) to send vaccine from the Global Emergency Stockpile (4). Usually, vaccine, syringes and safety boxes will be sent by air and arrive within a week (5). However, countries may choose to have syringes and safety boxes sent by sea, if injection material can be borrowed from the existing stock in country. The cost of sea freight is less expensive compared to air, but it may take up to 2 months before arrival in the country. UNICEF SD will keep the country informed about volume and date of arrival. Figure 1- Requesting process and roles of involved partners RD Requesting country submits documents Secretariat summons Committee Requesting country or agency 1 Secretariat may ask for clarification YF-ICG Secretariat 4 2 3 Committee approves request Secretariat authorizes UNICEF SD to dispatch vaccine YF-ICG Committee 5 UNICEF SD dispatches vaccine doses UNICEF SD Global emergency YF stockpile Version 2012 - May 4 Page 4 of 15

4. What are the criteria for the release of the vaccine? The YF-ICG prioritizes requests for vaccine on the basis of (i) emergency, and (ii) the risk of spread of the disease. Therefore, the decision is based on the following criteria related to information provided in the documents (the roman numerals refer to the paragraph numbers in the request): Emergency situation criteria: Number of people at risk at a certain time and place (Annex 2, sections I, IV) Evidence of an epidemic situation (Annex 2, sections I, II) Risk of spread criteria: Risk of spread to other areas/districts or bordering countries (Annex 2, sections I, IV, V) Vector density (Annex 2, section III) Number of non-immune people (Annex 2, sections IV, V) The number of vaccine doses finally delivered depends on the following criteria: Amount of doses available at global level Current epidemics in other countries Country's preparedness and readiness to conduct a mass vaccination campaign 5. How much does it cost? All countries should reimburse the costs of: 1. yellow fever vaccines 2. injection materials, and 3. freight and insurance. Version 2012 - May 5 Page 5 of 15

GAVI-eligible countries 2 may receive support for operational costs provided they submit a Vaccination Plan with a detailed budget for operational costs along with the request. The ICG Secretariat (WHO) will send a letter or email to the country requesting reimbursement of the emergency delivery. In this correspondence the country will be informed of the total amount that needs to be paid, the timeline for the payment (normally 60 days after reception of the vaccine), and of the reimbursement procedures. Only under exceptional circumstances (vaccine shortages), replenishment with vaccine instead of cash, may be accepted, and will be decided upon on case-by-case basis. 6. How to get vaccine when the ICG Stockpile is depleted? On rare occasions, the full number of vaccine doses approved may not be delivered due to a global shortage or competing priorities. The ICG Secretariat will inform countries when this applies. In the unlikely event that the ICG cannot release the vaccine as requested by the country or because the criteria are not met, vaccine can still be purchased directly through UNICEF Supply Division or the country s regular procurement mechanisms. Prices will then be dependent on market prices. 2 Countries which have a GNI per capita less than $ 1,000, for more reference see: http://www.gavialliance.org/support_to_country/who_can_apply/index.php Version 2012 - May 6 Page 6 of 15

YELLOW FEVER VACCINE REQUEST FOR EMERGENCY CAMPAIGNS ANNEX 1: ESSENTIAL APPLICATION INFORMATION The International Coordinating Group (ICG) on Vaccine Provision for Yellow Fever Control is a partnership between UNICEF, MSF, IFRC and WHO. The ICG's objective is to ensure rapid and equal access to vaccines bundled with injection materials for yellow fever outbreak response. The release of these emergency supplies constitutes an advance to the countries in outbreak situation; as such their reimbursement is required to maintain ICG stockpiles at constant levels. Country:. Date of Request:. Affected areas (towns/districts): Requesting agency /country:. Address: Focal person contact information: Name / First name... Tel. Mobile phone Fax Email To activate the ICG process for Yellow Fever vaccine distribution and support to outbreak response vaccination campaigns, please fill out and provide the following essential documents (incomplete requests will not be considered): 1. Mandatory forms The essential information in the following forms: 1.1. Yellow Fever Epidemiological Assessment Form (annex 2: pages 8 to 11) 1.2. Yellow Fever Vaccine Order Form (annex 3: pages 12 to 14) 2. Essential supporting documents The following information allows the ICG to evaluate the urgent character of the request: 2.1 Vaccination plan and detailed budget for the mass campaign 2.2 Outbreak investigation report 2.3 A spot map of the affected areas 2.4 Copy of the original Regional Reference Laboratory results Documents should be sent to (preferably by email): Email: outbreak@who.int and ICGsecretariat@who.int Fax N : 00 41 22 791 41 98 HSE/PED Yellow Fever focal point World Health Organization 20 avenue Appia, 1211 Geneva 27 - Switzerland (For detection, case definitions, investigation and procedure, follow guidance given in "Yellow fever surveillance and outbreak response: revision of case definitions, October 2010" Weekly Epidemiological Record, 2010, 85:465-472, http://www.who.int/wer/2010/wer8547/en/index.html Version 2012 - May 7 Page 7 of 15

YELLOW FEVER VACCINE REQUEST FOR EMERGENCY CAMPAIGNS ANNEX 2: YELLOW FEVER EPIDEMIOLOGICAL ASSESSMENT FORM Country:.. Date: I. Epidemiological description Please provide a line listing of the first Yellow fever cases sorted by date of onset of symptoms. You may add lines if necessary. Description of the first Yellow Fever cases Location of the cases Age Sex M / F Date of onset (dd/mm/yy) Alive Yes/ No YF Vaccination Yes (Date)* /No/ Unknown Laboratory Confirmation Status ** Province and District Sub-District Place of infection * If date of last YF vaccination available, please provide the date. In case only oral vaccination history can be confirmed, please mark yes/no and leave the date out. ** Laboratory confirmation status: 0 = yellow fever not confirmed; 1= yellow fever confirmed; 2 = Result pending Total number of cases (suspected, probable and confirmed), including deaths: Total number of laboratory confirmed cases: Total number of deaths: Period of the rainy season period in the location investigated: Date of onset of the last reported YF case related to this outbreak:... Version 2012 - May 8 Page 8 of 15

II. Laboratory confirmation summary Please summarize the laboratory findings from national and reference laboratories by providing the number of positive, negative and pending results. Please provide the titer, in parenthesis, when available. Laboratory name Number of specimens tested IgM YF (titer) IgM Differential diagnosis Results PRNT YF (titer) PCR YF * IgM positive for yellow fever and negative to other flaviviruses (at a minimum dengue and West Nile virus) PRNT = plaque reduction neutralization test. III. Entomological investigation Has an entomological investigation been performed? Yes No If yes, please complete the table: Location Investigated Type of vector found If Aedes aegypti indicate Stegomyia Indices Breteau index House index Container index Adult collection Yes/No Vector RT-PCR Breteau index = (Number of positive containers / Number of houses inspected) X 100 House index = (Number of infested houses / Number of houses inspected) X 100 Container index = (Number of positive containers / Number of containers inspected) X 100 RT - PCR = Real time polymerase chain reaction Version 2012 - May 9 Page 9 of 15

IV. Affected population and Yellow Fever vaccination coverage (%) Please indicate the vaccine coverage of the affected population for the last 10 years, including the year of coverage data. Year Name of location Type of location * Population Vaccination coverage % Number Routine EPI ** Preventive campaign Emergency campaign * Example: Sub district (SD), District (D), Province (P), Region (R) ** EPI = Expanded Programme on Immunization V. Previous Yellow Fever outbreaks Please give brief information about history of Yellow Fever in the country and/or affected region/s during the past 10 years: Affected location Date of outbreak Number of cases Number of deaths Vaccination Yes / No Number of Yellow Fever vaccine doses used Version 2012 - May 10 Page 10 of 15

VI. Organization of the response Has a national epidemic coordination committee been established to plan and monitor outbreak response activities? Yes No Please describe briefly the composition of the committee and actions already taken:.................. Comments: Version 2012 - May 11 Page 11 of 15

YELLOW FEVER VACCINE REQUEST FOR EMERGENCY CAMPAIGNS ANNEX 3: YELLOW FEVER VACCINE ORDER FORM Country: Date:. I. Yellow Fever Vaccine Please provide the following information regarding the planned vaccination campaign: Planned date for the start of the campaign (dd/mm/yyyy):.. Estimated duration of the campaign:... Geographical area(s) for vaccination Target age groups Number of target population Number of vaccine doses 3 Total number of target population: Total number of requested doses: Do you have a stock of yellow fever vaccine you can use while the vaccines arrive? Yes No If yes, please provide number of doses and expiry date: Number of doses in stock:.. Expiry date:.. Nota Bene: The vaccine doses come as "bundled vaccine" i.e. auto-disable syringes, reconstitution syringes and safety boxes. However materials and vaccines may arrive at different times (according to section III). 3 Note that the total number of YF vaccine doses needed is calculated by the following formula: Total vaccine doses required = targeted population x wastage factor (1.11) Version 2012 - May 12 Page 12 of 15

II. Vaccination Cards The distribution of vaccination cards is required during all yellow fever vaccination campaigns. Can vaccination cards be made available locally for the planned emergency campaign? Yes No If no, please note that vaccination cards will be shipped by the ICG. III. Injection Materials The appropriate quantity of vaccination materials will be systematically sent by the ICG whenever vaccine is released, according to WHO recommendations on injection devices security and supply (bundle policy) (http://www.who.int/injection_safety/whoguidprinciplesinjequipfinal.pdf). However, considering the high costs linked to the freight of these voluminous items, transport by boat may be chosen if the necessary vaccination materials can be locally borrowed and made available to perform the vaccinations. Therefore, in order to facilitate the choice of adequate transportation mode, please indicate the local availability of injection materials: Number of auto-disable syringes available:.. Number of reconstitution syringes available:.. Number of safety boxes available:. Expiry date:. Expiry date:. Expiry date:. The vaccination campaign may start with injection material from your stock and be replenished with syringes sent from the ICG's Yellow Fever emergency stockpile. In this case, when do you need the injection materials to arrive in the country?.. IV. Vaccine and material reception Please provide the below information for the reception of the vaccine and materials in the country: Consignee in the country Consignee organization Contact name Phone Fax Email Address P.O. Box Town Country Version 2012 - May 13 Page 13 of 15

V. Operational Costs A financial support to emergency vaccination campaign operational costs can be requested to the ICG. This contribution will be allocated according to available resources. Do you wish to apply for financial support 4 for operational costs? Yes No If so, it is essential that a detailed budget of the campaign be submitted with the YF vaccine request form. VI. Vaccine Reimbursement In order to ensure the sustainability of its stock, the ICG requires the reimbursement of the requested vaccines and materials. The requesting country or agency is expected to reimburse the costs of vaccines and injection materials delivered from the ICG stock (including safety boxes, auto disable and reconstitution syringes), as well as packing costs, insurance and shipment. This applies both to GAVI eligible and non eligible countries. Following delivery of the medical supplies, the ICG secretariat (WHO) will send an official communication requesting for reimbursement of their costs. The country or organization should transfer the funds as instructed and in accordance with WHO administrative procedures and regulations, within 60 days of reception of the medical supplies. Has funding been secured for replenishing the global emergency YF vaccine stockpile? Yes No Please provide below the following information: Information concerning reimbursement Source of funding/payment. Contact person. Email Phone number.. 4 Only applicable to GAVI-eligible countries. Version 2012 - May 14 Page 14 of 15

VII. Campaign Activity Report At the end of the vaccination campaign, you will be responsible for providing a vaccination campaign activity report, in order for the ICG to assess the vaccination results (use of the vaccine doses sent). Furthermore, for emergency mass campaigns of a target population of over 100,000 people, vaccination coverage survey data should be provided in this activity report. This report will also serve as a justification document for donors, which provide funds for the constitution of the vaccines and injection materials emergency stockpiles, as well as financial support to operational costs. Version 2012 - May 15 Page 15 of 15